The Oncology Institute, Inc. · NASDAQ:TOI
The Oncology Institute — Oncology Institute — Investor Presentation (August 2023)
22 slides from The Oncology Institute's investor presentation, Aug 10, 2023
Slide 1: Investor Presentation August 2023
1THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Investor Presentation AUGUST 2023
Slide 2: Disclaimer
2THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Disclaimer FORWARD LOOKING STATEMENTS This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform A
Slide 3: A unique value-based model disrupting Oncology Care
3THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Our technology platform is the first to standardize and align care delivery at scale, while proving our model with new market exportability. TOI’s future growth and new market entry is predictable, repeatable and scalable with tremendous near term and lon
Slide 4: Rising cost of Oncology Care is a massive problem in the U.S.
4THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Rising cost of Oncology Care is a massive problem in the U.S. of U.S. GDP is spent on healthcare and rising18% Healthcare is Unaffordable & Inefficient in the U.S. spent per person compared to OECD average2x Yet, U.S. incidence of chronic illness and long
Slide 5: Revenue and Milestone Timeline
5THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Revenue(1) and Milestone Timeline TOI represents 0.01% of the U.S. Oncology Market providing substantial growth opportunity Notes: (1) 2007-2017 revenue is cash basis, unaudited and pertains to the Predecessor entity only (2) Predecessor revenue of $76M;
Slide 6: Disrupting the Status Quo in Cancer Care
6THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Disrupting the Status Quo in Cancer Care ✓ Incentivized by quality ✓ Incentivized to use high-value therapies ✓ Physician compensation model aligned to quality and patient satisfaction ✓ Practice tailored to address individualized patient needs ✓ Supporte
Slide 7: We are building the leading Value-Based Oncology Care Platform
7THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION unique patients treated each year~64K lives served under capitation~1.8M clinical trials giving patients cutting edge access170+ We are building the leading Value-Based Oncology Care Platform reduction in patient healthcare costs25%+ Revenue generated fro
Slide 8: Our results are peer-reviewed & published
8THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Our results are peer-reviewed & published (1) Based on study on TOI patient population conducted by researchers at Stanford University; (2) As of April 11, 2021 (5.0 scale). Lower Inpatient Admissions(1)30% Improvement in Patient Satisfaction(2)14% Fewer
Slide 9: Our patient-centric focus drives high levels of satisfaction
9THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION “ “ “ Our patent-centric focus drives high levels of satisfaction “Thank you all for helping me through this life test…From the front desk to the specialist – when it comes to cancer, you are all needed and appreciated; your kindness and selflessness make
Slide 10: We use multiple levers to reduce cost of care
10THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION We use multiple levers to reduce cost of care Effective Treatments • Reduce practice pattern variability • Access to clinical trials in the community • Vertical integration of dispensary and scaled drug purchasing High-Value Cancer Care Program • Algorit
Slide 11: Proven portability with a rapidly expanding footprint
11THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Proven portability with a rapidly expanding footprint California Clinics 48 Florida Clinics 8 Arizona Clinics 4 Nevada Clinics 5 Texas Clinics 2
Slide 12: Strong unit economics drives increasing profitability
12THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Strong unit economics drives increasing profitability 10% 15% 20% 25% 30% 35% 40% 20% 30% 40% 50% 60% 70% 80% 90% Po d G ro ss M ar gi n Pod % Value-Based Visits ↑ ↑ TOI Pod(2): Gross Margin vs. % Value-Based Visits Embedded gross margin expansion potent
Slide 13: Multiple levers to sustain long term growth trajectory
13THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Existing Markets Continue driving growth in lives and partnership expansion + New contracts + Expand covered lives + New clinics & providers + Improve unit economics + Medicare direct contracting New Markets Well-honed model enables quick scaling in new
Slide 14: Financial Overview
14THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Financial Overview
Slide 15: Diversified business model with multiple drivers of revenue growth
15THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Diversified business model with multiple drivers of revenue growth and margin expansion + Medicaid + Medicare + Commercial Patient Care (Medical & Radiation Oncology) Drug Dispensing Clinical Trials Data Monetization Management Services Products Covered
Slide 16: Value driven highly attractive economic model
16THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Value driven highly attractive economic model Payor Contracts Provider Contracts FFS Driven; High Cost for Payors and Risk-Taking Providers Unmanaged or Under-managed Oncology Market TOI saves payors 25%+ of medical oncology costs Pool of lives managed b
Slide 17: 2023 Guidance
17THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION 2023 Guidance REVENUE $290 to $320 million representing approximately 15% to 27% growth over 2022 revenue GROSS PROFIT $60 to $70 million ADJUSTED EBITDA $(25) to $(28) million VALUE-BASED LIVES 1.75 to 2 million lives Note: TOI's achievement of the anti
Slide 18: Key Takeaways
18THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Key Takeaways ✓ Early market leader in large & growing market ✓ Proven model with imbedded scalability ✓ Well capitalized, with disciplined deployment strategy ✓ Our platform growth enables high-quality, affordable care for more patients
Slide 19: Historical Financials
19THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Historical Financials
Slide 20: 20THE Patient services $ 35,057 $ 39,109 $ 44,627 $ 47,992 $ 50,273 $
20THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Patient services $ 35,057 $ 39,109 $ 44,627 $ 47,992 $ 50,273 $ 53,426 $ 116,817 $ 124,074 $ 166,785 Dispensary 18,679 20,218 18,839 21,607 24,240 25,196 63,890 72,550 79,343 Clinical trials & other 1,425 1,594 1,511 1,825 1,679 1,602 6,808 6,379 6,355 T
Slide 21: 21THE FOR YEAR ENDED Mar 31, 2022 FOR THREE MONTHS ENDED Jun 30, 2022
21THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION FOR YEAR ENDED Mar 31, 2022 FOR THREE MONTHS ENDED Jun 30, 2022 Sept 30, 2022 Dec 31, 2022 Mar 31, 2023 Jun 30, 2023 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 IN C O M E (L O SS ) Loss from operations (18,471) (18,304) (20,097) (25,079) (32,867) (14,938) (8
Slide 22: 22THE FOR YEAR ENDED Mar 31, 2022 FOR THREE MONTHS ENDED Jun 30, 2022
22THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION FOR YEAR ENDED Mar 31, 2022 FOR THREE MONTHS ENDED Jun 30, 2022 Sept 30, 2022 Dec 31, 2022 Mar 31, 2023 Jun 30, 2023 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Net (loss) income $ 19,286 $ (5,453) $ (2,674) $ (11,007) $ (29,998) $ (16,897) $ (14,322) $ (10,9
Oncology Institute — Investor Presentation (August 2023) on 6ix